Editas Medicine, Inc. (EDIT) stock
EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3038% above fair value
$2.17+0.03 (+1.40%)
Close on Nov 13, 2026Market cap $333.27MP/E –Yield –
Editas Medicine operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Editas Medicine's operating income for the twelve months ending Sep 30, 2026 was -$75.59M. For fiscal 2025 it was -$160.01M. The highest annual figure on record is -$12.72M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$160.01M | – |
| FY2024 | Dec 31, 2024 | -$251.15M | – |
| FY2023 | Dec 31, 2023 | -$169.18M | – |
| FY2022 | Dec 31, 2022 | -$225.95M | – |
| FY2021 | Dec 31, 2021 | -$193.15M | – |
| FY2020 | Dec 31, 2020 | -$134.84M | – |
| FY2019 | Dec 31, 2019 | -$140.92M | – |
| FY2018 | Dec 31, 2018 | -$113.73M | – |
| FY2017 | Dec 31, 2017 | -$119.93M | – |
| FY2016 | Dec 31, 2016 | -$97.19M | – |
| FY2015 | Dec 31, 2015 | -$35.31M | – |
| FY2014 | Dec 31, 2014 | -$12.72M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$24.28M | – |
| Q2 FY2026 | Jun 30, 2026 | -$18.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.76M | – |
| Q3 FY2025 | Sep 30, 2025 | -$24.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$51.54M | – |
| Q1 FY2025 | Mar 31, 2025 | -$76.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$46.59M | – |
| Q3 FY2024 | Sep 30, 2024 | -$65.67M | – |
| Q2 FY2024 | Jun 30, 2024 | -$71.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$66.99M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$50.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$44.09M | – |
| Q1 FY2023 | Mar 31, 2023 | -$50.96M | – |
| Q4 FY2022 | Dec 31, 2022 | -$63.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$57.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$54.23M | – |
| Q1 FY2022 | Mar 31, 2022 | -$50.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$41.61M | – |
| Q3 FY2021 | Sep 30, 2021 | -$39.25M | -536.7% |
| Q2 FY2021 | Jun 30, 2021 | -$55.40M | – |
| Q1 FY2021 | Mar 31, 2021 | -$56.88M | – |
| Q4 FY2020 | Dec 31, 2020 | -$65.87M | – |
| Q3 FY2020 | Sep 30, 2020 | $8.99M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.34M | – |
| Q1 FY2020 | Mar 31, 2020 | -$46.62M | – |
| Q4 FY2019 | Dec 31, 2019 | -$39.42M | – |
| Q3 FY2019 | Sep 30, 2019 | -$34.59M | – |
| Q2 FY2019 | Jun 30, 2019 | -$35.65M | – |
| Q1 FY2019 | Mar 31, 2019 | -$31.26M | – |
| Q4 FY2018 | Dec 31, 2018 | -$26.25M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.26M | – |
| Q2 FY2018 | Jun 30, 2018 | -$39.66M | – |
| Q1 FY2018 | Mar 31, 2018 | -$31.56M | – |
| Q4 FY2017 | Dec 31, 2017 | -$36.44M | – |
| Q3 FY2017 | Sep 30, 2017 | -$26.75M | – |
| Q2 FY2017 | Jun 30, 2017 | -$26.12M | – |
| Q1 FY2017 | Mar 31, 2017 | -$30.63M | – |
| Q4 FY2016 | Dec 31, 2016 | -$38.98M | – |
See a number that looks wrong?